Table 3.
Association of HTLV-I viral markers with immune marker levels among Japanese and Jamaican carriers
| A. Anti-HTLV-I titer and HTLV-I provirus load | ||||
|---|---|---|---|---|
| Geographic population | ||||
| HTLV-I viral marker/Immune marker | Japan | Jamaica | ||
| r† | (p-value) | r† | (p-value) | |
| Anti-HTLV-I titer | ||||
| anti-EBNA2 | 0.07 | (0.66) | 0.28 | (0.06) |
| anti-VCA | 0.26 | (0.08) | 0.32 | (0.03) |
| anti-EA | 0.36 | (0.01) | 0.47 | (0.001) |
| sIL2R | 0.19 | (0.22) | 0.57 | (<0.0001) |
| sCD30 | -0.07 | (0.63) | 0.47 | (0.0009) |
| neopterin | 0.19 | (0.21) | 0.58 | (<0.0001) |
| HTLV-I provirus load | ||||
| anti-EBNA2 | 0.18 | (0.24) | 0.44 | (0.002) |
| anti-VCA | 0.07 | (0.67) | 0.07 | (0.64) |
| anti-EA | 0.22 | (0.15) | 0.31 | (0.03) |
| sIL2R | 0.22 | (0.14) | 0.58 | (<0.0001) |
| sCD30 | 0.08 | (0.61) | 0.49 | (0.0006) |
| neopterin | 0.08 | (0.61) | 0.57 | (<0.0001) |
| B. Anti-Tax seropositivity | ||||
| Immune marker | OR‡ | (95% CI) | OR‡ | (95% CI) |
| Anti-EBNA1 < median | 3.2 | (0.8-12.4) | 1.4 | (0.4-4.6) |
| Anti-EBNA2 > median | 2.0 | (0.6-6.7) | 1.5 | (0.4-5.2) |
| EBNA1:EBNA2 ratio ≤1.0 | 3.6 | (0.8-15.1) | 0.9 | (0.3-3.3) |
| Anti-EA-positive | 2.3 | (0.5-11.0) | 0.7 | (0.2-2.7) |
| sIL2R > median | 1.3 | (0.4-4.5) | 2.7 | (0.7-11.2) |
| sCD30 > median | 1.7 | (0.4-6.4) | 2.8 | (0.7-11.3) |
| Neopterin > median | 1.8 | (0.5-6.9) | 3.4 | (0.9-12.6) |
Abbreviations:HTLV-I, human T-lymphotropic virus type I; sIL2R, soluble IL-2 receptor; sCD30, soluble CD30; OR, odds ratio; CI, confidence interval; EBNA1, Epstein-Barr virus nuclear antigen type 1; EBNA2, Epstein-Barr virus nuclear antigen type 2;VCA, viral capsid antigen; EA, early antigen.
†
Spearman partial correlations of log10-transformed HTLV-I viral markers with log10-transformed serologic immune marker levels, with mutual adjustment for the immune markers and for age, sex, and year of sample collection.
‡
From logistic regression models adjusted for age, sex, and year of sample collection.